Cas no 116355-83-0 (Fumonisin B1)
Fumonisin B1 Chemical and Physical Properties
Names and Identifiers
-
- 1,2,3-Propanetricarboxylicacid,1,1'-[(1S,2R)-1-[(2S,4R,9R,11S,12S)-12-amino-4,9,11-trihydroxy-2-methyltridecyl]-2-[(1R)-1-methylpentyl]-1,2-ethanediyl]ester, (2R,2'R)-
- Fumonisin B1
- Fumonisin B1 solution
- FUMONISIN B1(RG)
- MaizeFlourwithFumonisinB1
- Fumonisin B1 from Fusarium moniliforme,Macrofusine
- Fumonisin B1,1,1'-[(1S,2R)-1-[(2S,4R,9R,11S,12S)-12-Amino-4,9,11-trihydroxy-2-methyltridecyl]-2-[(1R)-1-methylpentyl]-1,2-ethanediyl-1,2,3-(2R,2'R)-propanetricarboxylicacidester.
- (2R,2'R)-1,2,3-Propanetricarboxylic acid 1,1'-[(1S,2R)-1-[(2S,4R,9R,11S,12S)-12-amino-4,9,11-trihydroxy-2-methyltridecyl]-2-[(1R)-1-methylpentyl]-1,2-ethanediyl] ester
- FB1
- MACROFUSINE
- FUMONISIN B1, FUSARIUM MONILIFORME
- FUMONISIN B1 FROM FUSARIUM MONILIFORME
- FUMONISIN B1 98%
- Fumonisin B1,96%
- Fumonisin B1 ,95%
- fumonisin b1solution
- FuMonisin B1, 96% 1MG
- CCRIS 4433
- fumonisin B(1)
- HSDB 7077
- NSC-629151
- 19 - Fusarium mycotoxins in oats
- 1,1'-[(1S,2R)-1-[(2S,4R,9R,11S,12S)-12-Amino-4,9,11-trihydroxy-2-methyltridecyl]-2-[(1R)-1-methylpentyl]-1,2-ethanediyl-1,2,3-(2R,2'R)-propanetricarboxylic acid ester.
- CS-0029116
- NSC 629151
- EX-A8017
- AKOS024457430
- CHEBI:38221
- SCHEMBL13555629
- GLXC-25523
- 1ST7224-100M
- (2R)-2-[2-[(5R,6R,7S,9S,11R,16R,18S,19S)-19-amino-6-[(3R)-3,4-dicarboxybutanoyl]oxy-11,16,18-trihydroxy-5,9-dimethylicosan-7-yl]oxy-2-oxoethyl]butanedioic acid
- 1,2,3-PROPANETRICARBOXYLIC ACID, 1,1'-((1S,2R)-1-((2S,4R,9R,11S,12S)-12-AMINO-4,9,11-TRIHYDROXY-2-METHYLTRIDECYL)-2-((1R)-1-METHYLPENTYL)-1,2-ETHANEDIYL) ESTER, (2R,2'R)-
- 116355-83-0
- fumonisin-B1
- LMSP01080022
- 1,2,3-Propanetricarboxylic acid, 1,1'-(1-(12-amino-4,9,11-trihydroxy-2-methyltridecyl)-2-(1-methylpentyl)-1,2-ethanediyl)ester
- HY-N6719
- UNII-3ZZM97XZ32
- 1,2,3-Propanetricarboxylic acid, 1,1'-(1-(12-amino-4,9,11-trihydroxy-2-methyltridecyl)-2-(1-methylpentyl)-1,2-ethanediyl) ester
- 3ZZM97XZ32
- Fumonisin B1 50 microg/mL in Acetonitrile/Water
- FUMONISIN B1 [IARC]
- DTXSID6020644
- Fumonisin B1 solution in Methanol, 100ug/mL
- Fumonisin B1 solution in Acetonitrile/Water (1:1), 50ug/mL
- FUMONISIN B1 [MI]
- Fumonisin B1, reference material
- (2R,2'R)-2,2'-{[(5R,6R,7S,9S,11R,16R,18S,19S)-19-amino-11,16,18-trihydroxy-5,9-dimethylicosane-6,7-diyl]bis[oxy(2-oxoethane-2,1-diyl)]}dibutanedioic acid
- 1,2,3-Propanetricarboxylic acid, 1,1'-[1-(12-amino-4,9,11-trihydroxy-2-methyltridecyl)-2-(1-methylpentyl)-1,2-ethanediyl] ester, [2S-[1[1R*(S*),2S*(S*),2(S*)],2R*,4S*,9S*,11R*,12R*]]-; Fumonisin B1
- Fumonisin B1 from Fusarium moniliforme, >=98% (HPLC)
- 1ST7224
- 1,2,3-Propanetricarboxylic acid, 1,1'-[(1S,2R)-1-[(2S,4R,9R,11S,12S)-12-amino-4,9,11-trihydroxy-2-methyltridecyl]-2-[(1R)-1-methylpentyl]-1,2-ethanediyl] ester, (2R,2'R)-
- (R)-3-Carboxy-pentanedioic acid mono-{(1S,3S,5R,10R,12S,13S)-13-amino-1-[(1R,2R)-1-((R)-3,4-dicarboxy-butyryloxy)-2-methyl-hexyl]-5,10,12-trihydroxy-3-methyl-tetradecyl} ester
- Q63395324
- 1ST7224-50A
- C19241
- FUMONISINB1
- (2S)-2-[2-[(5R,6R,7S,9S,11R,16R,18S,19S)-19-Amino-6-[(3S)-3,4-dicarboxybutanoyl]oxy-11,16,18-trihydroxy-5,9-dimethylicosan-7-yl]oxy-2-oxoethyl]butanedioic acid
- (2S,2'S)-2,2'-{[(5S,6R,7R,9R,11S,16R,18S,19S)-19-amino-11,16,18-trihydroxy-5,9-dimethylicosane-6,7-diyl]bis[oxy(2-oxoethane-2,1-diyl)]}dibutanedioic acid
- J-003429
- CHEMBL91690
- Q420762
- SCHEMBL182919
- 2-[2-[13-amino-1-[1-(3-carboxy-5-hydroxy-5-oxo-pentanoyl)oxy-2-methyl-hexyl]-5,10,12-trihydroxy-3-methyl-tetradecoxy]-2-oxo-ethyl]butanedioic acid
- SR-01000721952-2
- NCI60_009465
- Fumonisin B1-13C34 solution
- 2,2'-{(19-Amino-11,16,18-trihydroxy-5,9-dimethylicosane-6,7-diyl)bis[oxy(2-oxoethane-2,1-diyl)]}dibutanedioic acid
- 2-[2-({19-amino-6-[(3,4-dicarboxybutanoyl)oxy]-11,16,18-trihydroxy-5,9-dimethylicosan-7-yl}oxy)-2-oxoethyl]butanedioic acid
- 1ST7224C34-25M
- CHEMBL1588379
- NSC629151
- BCP31144
- UVBUBMSSQKOIBE-UHFFFAOYSA-N
- SCHEMBL182918
- 1,2,3-Propanetricarboxylic acid, 1,-1'-[1-(12-amino-4,9,11-trihydroxy-2-methyltridecyl)-2-(1-methylpentyl)-1,2-ethanediyl] ester
- DTXSID80861237
- MLS000517270
- CHEBI:185259
- Fumonisin B1-13C34 Solution in Acetonitrile, 25ug/mL
- 1217458-62-2
- Fungal metabolite from Fusarium monliforme
- SMR000127506
- NS00000145
- FT-0626567
- 2-[2-[19-amino-6-(3,4-dicarboxybutanoyloxy)-11,16,18-trihydroxy-5,9-dimethylicosan-7-yl]oxy-2-oxoethyl]butanedioic acid
- Macrofusin
- SMP1_000324
- SR-01000721952
- 2-(2-((13-Amino-1-(1-((3,4-dicarboxybutanoyl)oxy)-2-methylhexyl)-5,10,12-trihydroxy-3-methyltetradecyl)oxy)-2-oxoethyl)succinic acid
- HMS2268H15
- MLSMR
- CHEMBL5282242
- G14340
- 1,2,3-Propanetricarboxylic acid, 1,1'-(1-(12-amino-4,9,11-trihydroxy-2-methyltridecyl)-2-(1-methylpentyl)-1,2-eth anediyl) ester
- DTXCID60644
- 2-(2-(19-amino-6-(3,4-dicarboxybutanoyloxy)-11,16,18-trihydroxy-5,9-dimethylicosan-7-yl)oxy-2-oxoethyl)butanedioic acid
- (2S)-2-(2-{[(5R,6R,7S,9S,11R,16R,18S,19S)-19-amino-6-{[(3S)-3,4-dicarboxybutanoyl]oxy}-11,16,18-trihydroxy-5,9-dimethylicosan-7-yl]oxy}-2-oxoethyl)butanedioate
- FUMONISIN B1 (IARC)
- 1,2,3Propanetricarboxylic acid, 1,1'(1(12amino4,9,11trihydroxy2methyltridecyl)2(1methylpentyl)1,2ethanediyl) ester
- (2S)-2-(2-(((5R,6R,7S,9S,11R,16R,18S,19S)-19-amino-6-(((3S)-3,4-dicarboxybutanoyl)oxy)-11,16,18-trihydroxy-5,9-dimethylicosan-7-yl)oxy)-2-oxoethyl)butanedioate
- DA-53128
- 1,2,3-Propanetricarboxylic acid, 1,-1'-(1-(12-amino-4,9,11-trihydroxy-2-methyltridecyl)-2-(1-methylpentyl)-1,2-ethanediyl) ester
- Macrofacine
- UVBUBMSSQKOIBE-DSLOAKGESA-N
- 2-(2-((19-amino-6-((3,4-dicarboxybutanoyl)oxy)-11,16,18-trihydroxy-5,9-dimethylicosan-7-yl)oxy)-2-oxoethyl)butanedioic acid
- (2R,2'R)-2,2'-(((5R,6R,7S,9S,11R,16R,18S,19S)-19-amino-11,16,18-trihydroxy-5,9-dimethylicosane-6,7-diyl)bis(oxy(2-oxoethane-2,1-diyl)))dibutanedioic acid
-
- MDL： MFCD27977580
- Inchi： 1S/C34H59NO15/c1-5-6-9-20(3)32(50-31(44)17-23(34(47)48)15-29(41)42)27(49-30(43)16-22(33(45)46)14-28(39)40)13-19(2)12-24(36)10-7-8-11-25(37)18-26(38)21(4)35/h19-27,32,36-38H,5-18,35H2,1-4H3,(H,39,40)(H,41,42)(H,45,46)(H,47,48)/t19-,20+,21-,22+,23+,24+,25+,26-,27-,32+/m0/s1
- InChI Key： UVBUBMSSQKOIBE-DSLOAKGESA-N
- SMILES： O(C(C[C@H](C(=O)O)CC(=O)O)=O)[C@@H](C[C@@H](C)C[C@@H](CCCC[C@H](C[C@@H]([C@H](C)N)O)O)O)[C@@H]([C@H](C)CCCC)OC(C[C@H](C(=O)O)CC(=O)O)=O
Computed Properties
- Exact Mass: 721.38800
- Monoisotopic Mass: 721.388
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 8
- Hydrogen Bond Acceptor Count: 16
- Heavy Atom Count: 50
- Rotatable Bond Count: 31
- Complexity: 1070
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 10
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- XLogP3: -0.5
- Topological Polar Surface Area: 289
Experimental Properties
- Color/Form: White to brown powder
- Density: 1.254±0.06 g/cm3 (20 oC 760 Torr),
- Boiling Point: 713.81°C (rough estimate)
- Flash Point: 6?°C
- Refractive Index: 1.6630 (estimate)
- Solubility: Very slightly soluble (0.12 g/l) (25 o C),
- PSA: 288.51000
- LogP: 3.26450
- Sensitiveness: Sensitive to light and humidity
- Solubility: Soluble in water
- Vapor Pressure: 0.0±0.6 mmHg at 25°C
Fumonisin B1 Security Information
-
Symbol:
- Signal Word：Warning
- Hazard Statement： H351
- Warning Statement： P281
- Hazardous Material transportation number：UN 3172
- WGK Germany：3
- Hazard Category Code： R40
- Safety Instruction： 36/37-16
- RTECS：TZ8350000
-
Hazardous Material Identification：
- Packing Group：III
- Hazard Level：6.1(b)
- HazardClass：6.1(b)
- PackingGroup：III
- Risk Phrases：R40
- Packing Group：III
- Safety Term：6.1(b)
- Storage Condition：storage at -4℃ (1-2weeks), longer storage period at -20℃ (1-2years)
Fumonisin B1 Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | F135527-5mg |
Fumonisin B1 |
116355-83-0 | ≥98% (HPLC) | 5mg |
￥6179.90 | 2023-09-02 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | F135527-1mg |
Fumonisin B1 |
116355-83-0 | ≥98% (HPLC) | 1mg |
￥1544.90 | 2023-09-02 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | F299685-1.2ml |
Fumonisin B1 |
116355-83-0 | 25μg/mL in acetonitrile | 1.2ml |
￥13389.90 | 2023-09-02 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R023629-1mg |
Fumonisin B1 |
116355-83-0 | 98% | 1mg |
￥1854 | 2024-05-26 | |
| ChemScence | CS-0029116-1mg |
Fumonisin B1 |
116355-83-0 | >99.0% | 1mg |
$219.0 | 2022-04-28 | |
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | F864689-1mg |
Fumonisin B1 |
116355-83-0 | ≥98% (HPLC) | 1mg |
￥1,399.00 | 2022-01-11 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | L-QE951-1mg |
Fumonisin B1 |
116355-83-0 | ≥98% (HPLC) | 1mg |
￥3586.0 | 2022-03-01 | |
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | 32936-5MG |
Fumonisin B1 |
116355-83-0 | 5mg |
￥8783.6 | 2024-12-26 | ||
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | 34139-1ML |
Fumonisin B1 |
116355-83-0 | 1ml |
￥3323.64 | 2023-10-24 | ||
| TRC | F862750-1mg |
Fumonisin B1 |
116355-83-0 | 1mg |
$ 173.00 | 2023-09-07 |
Fumonisin B1 Suppliers
Audited Supplier
Audited Supplier
Fumonisin B1 Related Literature
-
James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
-
Shivani Sharma,Chia-Ming Wu,Ranjit T. Koodali,N. Rajesh RSC Adv., 2016,6, 26668-26678
-
5. An investigation of the electrochemical delithiation process of carbon coated α-Fe2O3nanoparticlesAdrian Brandt,Florian Winter,Sebastian Klamor,Frank Berkemeier,Jatinkumar Rana,Rainer P?ttgen,Andrea Balducci J. Mater. Chem. A, 2013,1, 11229-11236
Additional information on Fumonisin B1
Fumonisin B1 (CAS No. 116355-83-0): A Comprehensive Overview of Its Structure, Bioactivity, and Recent Research Findings
Fumonisin B1, with the chemical identifier CAS No. 116355-83-0, is a mycotoxin produced by certain species of Fusarium fungi. This compound has garnered significant attention in the field of chemobiology due to its diverse pharmacological effects and implications in human health and agriculture. As a member of the fumonisin family, it shares structural similarities with other mycotoxins but exhibits distinct biological activities that make it a subject of extensive research.
The molecular structure of Fumonisin B1 consists of a triacetylated derivative of 3-amino-12,13-dihydroxy-9-methyltetradecanoic acid. This unique configuration contributes to its ability to interfere with sphingolipid biosynthesis, a critical pathway in cellular metabolism. The disruption of this pathway has been implicated in various pathological conditions, including cancer, neurodegenerative diseases, and metabolic disorders.
Recent studies have highlighted the multifaceted bioactivity of Fumonisin B1. For instance, research published in the journal Biochemical Pharmacology has demonstrated its potent inhibitory effects on the enzyme ceramide synthase, which is essential for sphingolipid production. This inhibition leads to an accumulation of ceramide precursors, triggering cellular stress responses such as apoptosis and autophagy.
In addition to its impact on sphingolipid metabolism, Fumonisin B1 has been shown to exhibit genotoxic and carcinogenic properties. A study published in the Journal of Applied Toxicology reported that long-term exposure to this mycotoxin could lead to DNA damage and chromosomal abnormalities in mammalian cells. These findings have raised concerns about its potential role in the development of certain cancers, particularly in regions where mycotoxin contamination is prevalent.
The agricultural significance of Fumonisin B1 cannot be overstated. Crops such as corn and peanuts are particularly susceptible to contamination by Fusarium species, leading to widespread presence of this mycotoxin in food supplies. Regulatory agencies worldwide have established guidelines to limit exposure levels, emphasizing the need for effective detection and mitigation strategies. Advances in analytical techniques, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS), have improved the accuracy and sensitivity of Fumonisin B1 detection in food matrices.
Recent research has also explored the therapeutic potential of Fumonisin B1. Surprisingly, some studies suggest that low doses of this compound may have protective effects against certain neurological disorders. For example, a study published in the Neurochemical Research journal indicated that pretreatment with Fumonisin B1 could mitigate neuronal damage caused by oxidative stress and excitotoxicity. However, these findings require further investigation to fully understand the mechanisms involved and to assess potential risks.
The toxicological profile of Fumonisin B1 is complex and influenced by various factors, including dosage, duration of exposure, and individual susceptibility. Animal models have been instrumental in elucidating its adverse effects on different organ systems. For instance, studies in rodents have shown that high levels of exposure can lead to liver damage, kidney dysfunction, and reproductive toxicity. These findings underscore the importance of implementing stringent safety measures in both agricultural practices and industrial settings where this compound may be present.
The interaction between Fumonisin B1 and host metabolism is another area of active investigation. Research suggests that genetic polymorphisms in enzymes responsible for detoxifying mycotoxins can influence an individual's susceptibility to their adverse effects. Understanding these genetic factors may help develop personalized approaches for risk assessment and mitigation strategies.
In conclusion, Fumonisin B1 (CAS No. 116355-83-0) is a multifaceted compound with significant implications for human health and agriculture. Its ability to disrupt sphingolipid biosynthesis and its associated toxicological effects make it a subject of intense research interest. While challenges remain in fully understanding its mechanisms of action and developing effective control measures, ongoing studies continue to shed light on its complex bioactivity and potential applications.
116355-83-0 (Fumonisin B1) Related Products
- 79367-52-5(1,2,3-Propanetricarboxylicacid,1-[(1S,3S,9R,10S,12S)-13-amino-9,10,12-trihydroxy-1-[(1R,2R)-1-hydroxy-2-methylbutyl]-3-methyltridecyl]ester, (2R)-)
- 149849-90-1(AAL Toxin TB1)
- 203259-29-4(1,2,3-Propanetricarboxylic acid, 1,1'-[(1S,2R)-1-[(2S,4R,10R,11R,12S)-12-amino-4,10,11-trihydroxy-2-methyltridecyl]-2-[(1R)-1-methylpentyl]-1,2-ethanediyl] ester, (2S,2'S)-)
- 136379-60-7(1,2,3-Propanetricarboxylicacid,1,1'-[(1S,2R)-1-[(2S,11S,12S)-12-amino-11-hydroxy-2-methyltridecyl]-2-[(1R)-1-methylpentyl]-1,2-ethanediyl]ester, (2R,2'R)-)
- 136379-59-4(1,2,3-Propanetricarboxylicacid,1,1'-[(1S,2R)-1-[(2S,4R,11S,12R)-12-amino-4,11-dihydroxy-2-methyltridecyl]-2-[(1R)-1-methylpentyl]-1,2-ethanediyl]ester)
- 79367-51-4(AAL Toxin TA2)
- 149849-91-2(AAL Toxin TB2)
- 172175-39-2(2-[2-[19-Amino-6-(3,4-dicarboxybutanoyloxy)-18-hydroxy-5,9-dimethylnonadecan-7-yl]oxy-2-oxoethyl]butanedioic acid)
- 116355-84-1(Fumonisin B2)
- 658057-49-9(D-chiro-Inositol, 1-amino-1,2,3-trideoxy-3-(ethoxycarbonyl)- (9CI))
